IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Bridges Investment Management Inc.

Bridges Investment Management Inc. decreased its position in IQVIA Holdings Inc. (NYSE:IQV) by 6.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 9,169 shares of the medical research company’s stock after selling 655 shares during the period. Bridges Investment Management Inc.’s holdings in IQVIA were worth $2,173,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Versant Capital Management Inc increased its stake in shares of IQVIA by 733.3% during the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 110 shares during the period. Opal Wealth Advisors LLC bought a new position in IQVIA during the 2nd quarter valued at $27,000. Capital Performance Advisors LLP acquired a new position in shares of IQVIA during the 3rd quarter valued at $27,000. Park Place Capital Corp bought a new stake in shares of IQVIA in the 3rd quarter worth $28,000. Finally, Itau Unibanco Holding S.A. acquired a new stake in shares of IQVIA in the second quarter valued at $29,000. Institutional investors own 89.62% of the company’s stock.

Insider Activity

In related news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares in the company, valued at approximately $4,812,302.88. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 1.60% of the stock is owned by insiders.

IQVIA Price Performance

Shares of IQV opened at $219.23 on Friday. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The firm has a market cap of $39.79 billion, a PE ratio of 28.77, a PEG ratio of 2.26 and a beta of 1.51. The firm’s 50 day moving average price is $231.00 and its 200 day moving average price is $229.31. IQVIA Holdings Inc. has a twelve month low of $190.20 and a twelve month high of $261.73.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Argus raised shares of IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Friday. BTIG Research dropped their target price on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Jefferies Financial Group downgraded shares of IQVIA from a “buy” rating to a “hold” rating and reduced their price target for the company from $266.00 to $242.00 in a research report on Wednesday, July 24th. Finally, UBS Group lifted their price objective on shares of IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. Five equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $259.13.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.